Array-based comparative genomic hybridization (array-CGH) has good potential for the high-throughput identification of genetic aberrations in cell genomes. In the course of a program to screen a panel of oral squamous-cell carcinoma (OSCC), cell lines for genomic copy-number aberrations by array-CGH using our in-house arrays, we identified a 3-Mb homozygous deletion at 10p12 in 1 of 18 cell lines (5.6%). Among seven genes located within this region, expression of PRTFDC1 mRNA was not detected in 50% (9/18) or decreased in 5.6% (1/18) of OSCC cell lines, but detected in normal oral epithelia and restored in gene-silenced OSCC cells without its homozygous loss after treatment with 5-aza-2′-deoxycytidine. Among 17 cell lines without a homozygous deletion, the hypermethylation of the PRTFDC1 CpG island, which showed promoter activity, was observed in all nine cell lines with no or reduced PRTFDC1 expression (52.9%). Methylation of this CpG island was also observed in primary OSCC tissues (8/47, 17.0%). In addition, restoration of PRTFDC1 in OSCC cells lacking its expression inhibited cell growth in colony-formation assays, whereas knockdown of PRTFDC1 expression in OSCC cells expressing the gene promoted cell growth. These results suggest that epigenetic silencing of PRTFDC1 by hypermethylation of the CpG island leads to a loss of PRTFDC1 function, which might be involved in squamous cell oral carcinogenesis.
Oral cancer, predominantly oral squamous-cell carcinoma (OSCC), is the most common head and neck neoplasm, affecting 270 000 people worldwide each year (Parkin et al., 2005). Despite recent progress in the diagnosis of and therapeutic modalities for OSCC, the prognosis has not been improved, reflecting the ineffectiveness of current treatment regimens (Parkin et al., 2005). A more comprehensive understanding of the molecular pathogenesis of OSCC is urgently needed to identify new targets and strategies for effective therapy, and the opportunity to recognize early OSCC and/or premalignant lesions may provide insight into the phase of new strategies for chemoprevention of this disease (Nagpal and Das, 2003; Brinkman and Wong, 2006). Although OSCC is believed to arise through the accumulation of numerous genetic and epigenetic alterations, which may impair the function of oncogenes or tumor suppressor genes (TSGs) that play a crucial role in the development of this disease (Scully et al., 2000; Ha and Califano, 2006), little is still known about the genes associated with oral carcinogenesis.
Although several TSGs, such as SMAD4, RB1, PTEN and p16INK4A, were originally identified from homozygous deletions in cancer cells (Friend et al., 1986; Kamb et al., 1994; Hahn et al., 1996; Li et al., 1997), genetic and epigenetic mechanisms other than homozygous loss could contribute to the loss of function of TSGs in tumors. Indeed, epigenetic inactivation of TSGs, including DNA hypermethylation in their CpG-rich promoter or exonic regions, has been believed to occur frequently and play important roles during the pathogenesis of human cancers, including oral cancer (Jones and Baylin, 2002; Ha and Califano, 2006). Hence, the mapping of homozygous deletions in OSCCs using high-throughput methods with high-resolution and sensitivity and further analyses of frequently inactivated ‘driver genes’ located within mapped regions may provide valuable clues for exploring OSCC-associated TSGs, even those whose inactivation occurs mainly by epigenetic mechanisms. Studies using chromosomal comparative genomic hybridization (CGH) and loss of heterozygosity analyses have attempted to identify copy-number alterations in a genome–wide manner, but are limited by the low resolution or the limited coverage of these technologies as a method to identify homozygous deletions. Array-based CGH (array-CGH) technique allows high-throughput and quantitative analyses of copy-number changes at high-resolution throughout the genome, providing many advantages, including the identification of homozygous loss, over conventional methods (Snijders et al., 2001; Inazawa et al., 2004), although the resolution fully depends on the type of array. Indeed, our previous array-CGH studies using in-house bacterial artificial chromosome- (BAC-)/P1-derived artificial chromosome- (PAC-) based arrays (BAC/PAC-arrays) have successfully mapped complete genetic losses, allowing the rapid identification of candidate TSGs inactivated mainly by genetic and/or epigenetic mechanisms (Sonoda et al., 2004; Izumi et al., 2005; Takada et al., 2005b, 2006; Imoto et al., 2006).
In the study reported here, we identified PRTFDC1 at 10p12 as a candidate target for a homozygously deleted region detected by array-CGH analyses using in-house BAC/PAC-arrays (MCG Cancer Array-800 and MCG Whole Genome Array-4500) against a panel of OSCC cell lines. Interestingly, expression of this gene was frequently silenced in OSCC cell lines without its homozygous loss, although it was present in normal oral mucosa, suggesting that PRTFDC1 may be inactivated epigenetically in a cancer-specific manner and contribute to oral carcinogenesis. To assess this hypothesis, we examined the role of DNA methylation within the CpG island around exon 1 of PRTFDC1 in regard to its expression in OSCC and tested the effect of PRTFDC1 expression on the growth of OSCC cells.
Results and discussion
In array-CGH analyses using MCG Cancer Array-800 and MCG Whole Genome Array-4500 arrays covering an entire genome with 5323 BAC/PAC clones, copy-number gains and losses were seen to some degree in all of the 18 OSCC cell lines examined (Figure 1a). Since the most common genetic aberrations had already been detected in OSCC cell lines and primary tumors by conventional CGH (Hermsen et al., 1997; Wolff et al., 1998), here, we paid attention to more remarkable patterns of chromosomal abnormalities, such as high-level amplifications and homozygous deletions, which are likely to be landmarks of oncogenes and TSGs, respectively (Baldwin et al., 2005; Snijders et al., 2005). Table 1, Table 2 summarize the clones showing high-level amplifications (log 2 ratio >2.0) or homozygous deletions (log 2 ratio<−2.0), respectively.
High-level amplifications were detected in 10 of the 18 OSCC cell lines (55.6%), and 15 loci were represented (Table 1). Among them, 7p11.2 containing EGFR is the only region amplified in more than two cell lines (four lines). On the other hand, two homozygous deletions were identified as novel loci for candidate TSGs in 2 of the 18 OSCC cell lines (Table 2). Although homozygous deletions of CDKN2A, a known tumor suppressor gene, at 9p21 have been detected by genomic PCR analysis in HOC-313, HOC-815 and OM-1 previously (Akanuma et al., 1999), our array-CGH analysis failed to detect this alteration probably, because the deletion was too small to be detected with the BAC/PAC-based array. We found a homozygous deletion at 2q24.1–q24.2 in the HO-1-N1 cell line; the region contains no genes whose expression decreased frequently in OSCC cell lines compared with normal oral epithelium (data not shown). In HSC-6 cells, we detected homozygous loss at 10p12. Since the region has been frequently involved in the loss of genetic material in primary OSCC (Jin et al., 2006), we focused on homozygous loss at 10p12 in HSC-6 to examine whether a TSG(s) related to the oral tumorigenesis might lie within this region.
Identification of gene(s) involved in the homozygous deletion at 10p12
To identify all potential target genes for the homozygous deletion at 10p12 in HSC-6 cells, we first tried to define the homozygously deleted region by genomic PCR using this cell line. The maximum extent of the homozygous deletion estimated from the result obtained with the array-CGH was approximately 2.95 Mb (Figure 1b, Figure 2a), and information archived by human genome databases (http://www.ncbi.nlm.nih.gov/ and http://genome.ucsc.edu/) indicated that seven genes are located in this region (Figure 2a). Among them, homozygous losses of PRTFDC1, c10orf63, THNSL1, GPR158, MYO3A and GAD2 (white arrows in Figure 2a) were detected in only HSC-6 cells (1/18, 5.6%; Figure 2b), whereas ARHGAP21 (black arrows in Figure 2a) was retained, narrowing down the region deleted to approximately 1.5 Mb (white closed arrow in Figure 2a).
Frequent loss of PRTFDC1 mRNA expression in OSCC cell lines
Next we determined expression levels of six genes, PRTFDC1, c10orf63, THNSL1, GPR158, MYO3A and GAD2, by means of reverse transcription (RT)–PCR in all 18 OSCC cell lines, RT7, an immortalized cell line derived from normal oral epithelial cells (Fujimoto et al., 2002), and primary cultured normal oral mucosa. The HSC-6 cell line as well as another eight lines without homozygous loss at 10p12 (9/18, 50%) completely lacked expression of PRTFDC1 mRNA; one line, HOC-313, (1/18, 5.6%) showed reduced expression compared with RT7 and/or primary cultured normal oral mucosa (Figure 2c and Supplementary Figure S1). No mutation was detected in any of coding exons of PRTFDC1 in all of cell lines tested except HSC-6 with homozygous loss of this gene (data not shown). On the other hand, the expression of c10orf63, THNSL1 and GPR158 was absent less frequently (Figure 2c), and GPR158 was not expressed in RT7 and primary cultured normal oral mucosa. In coding sequences of c10orf63 and THNSL, no mutation was also detected in all of cell lines tested except HSC-6 (data not shown). MYO3A and GAD2 were not expressed in RT7 and primary cultured normal oral mucosa probably due to their tissue-specific expression pattern, which is also described in expression databases (http://www.ncbi.nlm.nih.gov/ and http://www.lsbm.org/database/index.html), although these genes were not expressed in any of the OSCC cell lines (data not shown). Those results prompted us to focus on the PRTFDC1 gene as the most likely target for inactivation within the homozygously deleted region at 10p12, and suggest that frequent loss of PRTFDC1 mRNA expression in OSCC cell lines might result from mechanisms other than genomic deletion or mutation, including epigenetic events.
Effect of demethylation by 5-aza-2′-deoxycytidine on PRTFDC1 expression
Aberrant methylation of DNA within promoter regions harboring a larger than expected number of CpG dinucleotides is a key mechanism by which TSGs can be silenced (Jones and Baylin, 2002). To investigate whether demethylation could restore expression of PRTFDC1 mRNA, we treated OSCC cells lacking PRTFDC1 expression (ZA, NA and HSC-2) with 5-aza-2′-deoxycytidine (5-aza-dCyd), a methyltransferase inhibitor, for 5 days. PRTFDC1 mRNA was expressed in all cell lines after treatment with 5-aza-dCyd (Figure 2d). On the other hand, treatment with trichostatin A (TSA), a histone deacetylase inhibitor, alone had no affect on the expression of PRTFDC1. In addition, no enhancement of PRTFDC1 expression by 5-aza-dCyd given along with TSA was observed, indicating that histone deacetylation may play a minimal role in the transcriptional silencing of PRTFDC1 among OSCC cells.
Promoter activity of the PRTFDC1 CpG island
A 801-bp sequence around exon 1 of PRTFDC1 (Figure 3a) was identified as a CpG island by using the genome database (http://www.ebi.ac.uk/emboss/cpgplot/). To determine whether hypermethylation of CpG sites is associated with transcriptional silencing of the PRTFDC1 gene, we tested the promoter activity of this CpG island in OSCC cells (NA and HSC-2) using a 891-bp fragment (Fragment 1) covering the entire CpG island and 482-bp (Fragment 2) and 409-bp (Fragment 3) fragments covering uncommonly and commonly methylated regions, respectively, in cell lines without expression of PRTFDC1 (Figures 3a and b). We observed a remarkable increase in transcriptional activity of the reporter plasmid containing Fragments 1 and 3 compared with the mock reporter plasmid and reporter plasmid containing Fragment 2 in the plasmid-containing cell lines (Figure 3b), suggesting that the CpG island around exon 1 of PRTFDC1, especially the region commonly methylated in PRTFDC1-nonexpressing cell lines, contains promoter activity, although few studies, including ours, have shown that promoter activity can be observed in fragments, especially CpG islands, not containing a 5′ sequence around transcriptional start sites (Kolb 2003; Nakagawachi et al., 2003; Sonoda et al., 2004; Misawa et al, 2005).
Methylation status of the PRTFDC1 CpG island in OSCC cell lines and primary tumors
To clarify the role of methylation within the PRTFDC1 CpG island on the expression level of this gene, we first assessed the methylation status of this CpG island in OSCC cell lines with or without expression of this gene, by means of a combined bisulfite restriction analysis (COBRA) using appropriate restriction enzymes for each of the two PCR fragments covering the entire CpG island (Regions 1, 2 in Figure 3a). OSCC cell lines with clear PRTFDC1 expression (TSU, HOC-815, HSC-4, HSC-5, HSC-7, SKN-3, HO-1-N-1 and KOSC-2) and RT7 tended to be dominantly hypomethylated in both regions (Figure 3c). In nine OSCC cell lines that showed no or reduced PRTFDC1 expression without a homozygous deletion, on the other hand, dominant hypermethylation was observed in either of the regions, especially Region 2 (Figure 3c), which overlaps the sequence with significant promoter activity in vitro (Figure 3b), suggesting that methylation of CpG sites around Region 2 may play an important role in the silencing of PRTFDC1 expression. Since three of those nine cell lines (OM-2, ZA and NA; Supplementary Table S1) showed a hemizygous deletion pattern within the 10p12 region in our array-CGH analysis (log 2 ratio<−0.4), biallelic methylation or monoallelic methylation with loss of the heterozygous allele may be important for inactivating PRTFDC1 in OSCC, although its inactivation occurs mainly through the former mechanism.
To assess the methylation status of each CpG dinucleotide within the PRTFDC1 CpG island in more detail, we performed bisulfite sequencing in cell lines with or without the expression of PRTFDC1 (Figure 3d). CpG sites on the CpG island tended to be highly methylated in PRTFDC1-nonexpressing OSCC cells without homozygous deletion (ZA, HSC-2), whereas almost all CpG sites were unmethylated in one of the PRTFDC1-expressing OSCC cell lines (KOSC-2) and, in control RT7 cells. Notably, PRTFDC1 expression was retained in cell lines having alleles in which almost all the CpG sites were unmethylated (HOC-313 in Figure 3d), although % methylation in this line was similar to that in the cell line lacking PRTFDC1 expression (ZA in Figure 3d). A similar finding was observed in DNA from ZA and HSC-2 cells treated with 5-aza-dCyd (Figure 3d); those cells showed entirely unmethylated and partially or entirely methylated alleles simultaneously within the PRTFDC1 CpG island and restored PRTFDC1 mRNA expression after treatment with 5-aza-dCyd. Those findings suggest that an allele with almost entirely unmethylated CpG sites, especially in Region 2, through the CpG island might be needed for PRTFDC1 mRNA to be fully expressed.
Methylation status of the PRTFDC1 CpG island in primary tumors of OSCC
To determine whether hypermethylation of the PRTFDC1 CpG island also takes place in primary tumors of OSCC, we carried out COBRA using 47 cases of OSCC (Figure 4a). Methylated alleles in the PRTFDC1 CpG island were observed in 8 of 47 samples (17.0%), whereas the unmethylated allele was observed in all cases probably due to unavoidable contamination by noncancerous cells. Since the DNAs had been isolated from snap-frozen tumors, the lower frequency of methylation in primary tumors compared with cell lines could also reflect contamination of the specimens with noncancerous cells, leading to underestimation. To validate the methylation status of primary tumors in a more quantitative manner, we next performed bisulfite sequencing in some of the primary cases, and confirmed the more or less methylated CpG sites in COBRA-positive OSCC tissues (cases 68, 69 and 75, Figure 4b). As a result, hypomethylated alleles were also sequenced in COBRA-positive OSCC tissues again, probably owing to the normal tissue components included in tumor tissues (Figure 4b). Since methylated CpG sites in the PRTFDC1 CpG island were observed in primary OSCCs as well whereas the normal epithelial cell-derived cell line RT7 showed hypomethylation in this CpG island (Figures 3c and d), methylation of the PRTFDC1 CpG island did not arise during the passage of OSCC cell lines in vitro, but rather may be a true cancer-related event during oral carcinogenesis, although normal oral tissue corresponding to each tumor was not available to further confirm this supposition.
To determine the significance of the PRTFDC1 CpG island's methylation in the pathogenesis of OSCC, we first analysed the relationship between methylation status within Region 2 of the CpG island determined by COBRA (Figure 3a) and clinicopathological characteristics of all 47 primary tumors. The methylation status of the PRTFDC1 CpG island in each sample was not associated with gender, age, smoking or drinking history, histologic subtype (differentiation status), or tumor staging, although data were not fully available for some of those variables and only three cases of early stage tumor (stage I) were available for analysis (Table 3). Consequently, the methylation status of PRTFDC1 is unlikely to correlate with tumor behavior, although information on patient outcome was not available. However, among various TSGs, such as CDKN2B and 2A, CDH1, DAPK1, MGMT and DCC, whose methylation is known to be important in the development of OSCC (Ha and Califano, 2006; Shaw, 2006), only a few reports have shown a correlation between the methylation status of those genes and clinicopathological characteristics or prognosis (Shaw, 2006). Since there may be the potential for therapeutic and/or diagnostic advantages if specific aberrations could be shown to correlate with tumor behavior, further study using a larger set of cases, especially early stage tumors, will be necessary for those methylation-target genes including PRTFDC1 in OSCC.
Suppressive effect of PRTFDC1 expression on cell growth of OSCC cells
To gain further insight into the potential role of PRTFDC1 protein in oral carcinogenesis, we investigated whether restoration of PRTFDC1 expression would suppress growth of OSCC cells in which the gene had been silenced. We performed colony-formation assays (Sonoda et al., 2004) using the full coding sequence ofPRTFDC1 with a Myc-tag cloned into a mammalian expression vector (pCMV-3Tag4A-PRTFDC1) and cells lacking expression of PRTFDC1. As shown in Figure 5, 3 weeks after transfection and subsequent selection of drug-resistant colonies, the numbers of large colonies produced by PRTFDC1-transfected NA and OM-2 cells decreased compared to those produced by empty vector-transfected cells. We have not been able to obtain PRTFDC1-stable transfectants, which will be useful for further analyses of the tumor-suppressive function, from OSCC cell lines lacking expression of this gene (data not shown).
To confirm a growth-suppressive effect of PRTFDC1 in OSCC cells and exclude a possible non-specific toxicity of forced-expression of exogenous PRTFDC1 in colony-formation assay, we knocked down endogenously expressed PRTFDC1 by transient transfection of PRTFDC1-specific synthetic small interfering RNA (siRNA) to HO-1-N-1 and HSC-4 cell lines retaining expression of PRTFDC1 (Figure 5b). Transfection of PRTFDC1-siRNA effectively knockdown of expression level of PRTFDC1 mRNA compared with Luc-siRNA in both cell lines. Transfection of PRTFDC1-siRNA accelerated cell growth in those cell lines compared with Luc-siRNA transfected counterparts, although the efficiency of growth promoting effect of PRTFDC1-siRNA was different between two cell lines. Since transfection of PRTFDC1-siRNA to HSC-6 lacking expression of PRTFDC1 showed no effect on cell growth compared with Luc-siRNA (data not shown), growth promoting effect of PRTFDC1-siRNA transfection observed in HO-1-N1 and HSC-4 cell lines may not be caused by off-target effects or simple toxicity of siRNA used in this study. In fluorescence-activated cell sorting (FACS) analysis using HO-1-N-1 cell line, knockdown of PRTFDC1 resulted in a decrease in G0-G1 phase cells and an increase in S and G2-M phase cells (Figure 5b, lower), suggesting that PRTFDC1 may arrest OSCC cells at the G1-S checkpoint.
PRTFDC1 encodes a protein containing a phosphoribosyl transferase domain (http://www.ncbi.nlm.nih.gov/entrez). PRTFDC1 is highly homologous to HPRT1, hypoxanthine phosphoribosyl transferase 1; the mRNA-coding sequence has 68% homology, while the amino-acid sequence is also 68% homologous (Nicklas, 2006). According to the Homologene entry (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=homologene), this gene is conserved in vertebrates; this level of conservation implies that PRTFDC1 must be a functional gene, though its function is unknown. Our colony-formation assays using PRTFDC1-transfected OSCC cells and cell growth-assays using PRTFDC1-specific siRNA revealed growth-suppressive and/or anti-proliferative activity of the PRTFDC1 protein; neither had ever been demonstrated before. As no system we tried was successful for obtaining stable cell lines expressing PRTFDC1, it will be difficult to investigate the mechanisms of tumor-suppressing activity of PRTFDC1 any further. In addition, the expression analysis of PRTFDC1 mRNA in various human normal tissues was using real-time RT–PCR revealed differential expression pattern of this gene among tissues (Supplementary Figure S1), suggesting that significance of PRTFDC1 expression in carcinogenesis may be determined in a tissue-/cell-lineage-dependent manner. Since little information is available about the functional consequences of PRTFDC1's inactivation in terms of oral carcinogenesis as well as its substrates and/or physiological functions, additional studies should be designed to solve those issues.
In summary, we performed array-CGH using two types of in-house BAC/PAC-based genome arrays, covering the entire human genome with a total of 5323 BACs, to examine a panel of OSCC cell lines for copy-number alterations within smaller regions. From the homozygously deleted region at 10p12 detected in one cell line, we identified PRTFDC1 whose expression is frequently silenced as a consequence of DNA methylation within the CpG island having promoter activity and re-expression inhibits growth of OSCC cells lacking its expression, although its functional consequences in carcinogenesis remain unknown. Since methylation of the PRTFDC1 CpG island was observed in primary OSCC cases as well, future studies should focus on the determination of its potential as a marker for the detection of disease as well as disease status, prediction of outcome and sensitivity to chemotherapy.
Materials and methods
Cell lines and primary tumors
A total of 18 OSC cell lines (OM-1, OM-2, TSU, ZA, NA, Ca9–22, HOC-313, HOC-815, HSC-2, HSC-3, HSC-4, HSC-5, HSC-6, HSC-7, KON, SKN-3, HO-1-N-1 and KOSC-2) established from surgically resected tumors in Tokyo Medical and Dental University (Akanuma et al., 1999) or purchased from the Japanese Collection of Research Bioresources (Osaka, Japan) were maintained in Dulbecco's modified Eagle's MEM supplemented with 10% fetal bovine serum, and 100 units/ml penicillin/100 μg/ml streptomycin. The normal oral epithelial cell-derived cell line, RT7, was maintained in keratinocyte serum-free medium containing epidermal growth factor and bovine pituitary extract (Invitrogen, Carlsbad, CA, USA; Fujimoto et al., 2002).
Primary OSCC tumor samples were obtained during surgery from 58 patients who were treated at the National Cancer Institute or Chulalongkorn University, Bangkok, Thailand, with prior written consent from each patient and approval by the local ethics committee. None of the patients had been administered preoperative radiation, chemotherapy, or immunotherapy. Tissues from the patients were immediately frozen in liquid nitrogen and stored at −80°C until required. Genomic DNA and/or total RNA were isolated from each cell line or frozen primary tumor according to procedures described elsewhere. As control, we performed a primary culture of oral gingival epithelial cells (Kusumoto et al., 2004), obtained from a non-smoking healthy adult male under the approval for this study. RNA from various human normal tissues was purchased from Clontech (Mountain View, CA, USA).
Hybridizations were carried out as described elsewhere (Takada et al., 2005a, 2005b) with minor modifications using a hybridization machine (GeneTAC; Harvard Bioscience, Holliston, MA, USA). Hybridized slides were scanned with a GenePix 4000B (Axon Instruments, Foster City, CA, USA) and acquired images were analysed with GenePix Pro 6.0 imaging software (Axon Instruments). Fluorescence ratios were normalized so that the mean of the middle-third of log 2 ratios across the array was zero. Average ratios that deviated significantly (>2 s.d.) from zero were considered abnormal.
We screened DNAs from OSCC lines for homozygous losses by genomic PCR. All the relevant primer sequences are listed in Supplementary Table S2.
RT–PCR and real-time RT–PCR
Single-stranded cDNAs were generated from total RNAs. For RT–PCR, cDNAs were amplified with primers specific for each gene (Supplementary Table S2). The gene encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified at the same time to estimate the efficiency of cDNA synthesis.
For real-time RT–PCR, primer set and probe for PRTFDC1 were purchased from Applied Biosystems (TaqMan Gene Expression Assays; Foster City, CA, USA). The RT–PCR was performed using an ABI PRISM 7500 sequence detection System (Applied Biosystems) according to the manufacturer's instructions. Gene expression values are expressed as ratios (differences between the Ct values) between the genes of interest and an internal reference gene (GAPDH) that provides a normalization factor for the amount of RNA isolated from a specimen, and subsequently normalized with the value in the control cells (relative expression level). PCR amplifications were performed in triplicate for each sample.
We looked for mutations within coding sequence of each gene by means of exon amplification and direct sequencing, using primers designed for genomic sequences around each exon (Supplementary Table S2). Any base changes detected in samples were confirmed by sequencing each product in both directions.
Cells were treated with 0, 5, or 10 μ M of 5-aza-dCyd for 5 days without or with 100 ng/ml of TSA for the last 24 h.
Promoter reporter assay
A 891-bp fragment (Fragment 1 in Figure 3a) around the CpG island of PRTFDC1 predicted by the CpGPLOT program (http://www.ebi.ac.uk/emboss/cpgplot/) and fragments containing part of Fragment 1 (Fragments 2 and 3 in Figure 3a) were obtained by genomic PCR, and ligated into the pGL3-Basic vector (Promega, Madison, WI, USA). Reporter assay was performed as described elsewhere (Sonoda et al., 2004) using each construct or a control empty vector and an internal control pRL-hTK vector (Promega).
COBRA and bisulfite sequencing
Genomic DNAs were treated with sodium bisulfite, and subjected to PCR using primer sets designed to amplify the regions of interest, which were divided into two PCR fragments to analyse the entire sequences effectively (Supplementary Table S2). For COBRA, PCR products were digested with MluI or TaqI and electrophoresed (Xiong and Laird, 1997). For bisulfite sequencing, the PCR products were subcloned and then sequenced.
Transient transfection, western blotting and colony-formation assays
Two plasmids expressing C-terminally 3 × Myc-tagged PRTFDC1 (pCMV-3Tag4A-PRTFDC1) were obtained by cloning a full coding sequence of PRTFDC1 into the pCMV-3Tag4A vector (Stratagene, La Jolla, CA, USA) in-frame along with the Myc-epitope. pCMV-3Tag4A-PRTFDC1 or the empty vector (pCMV-3Tag4A-mock) control, were transfected into cells for colony formation assays as described elsewhere (Sonoda et al., 2004). The expression of PRTFDC1 protein in transiently transfected cells was confirmed 36 h after transfection by western blot analysis using anti-Myc antibody (Cell Signaling Technology, Beverly, MA, USA), as described elsewhere (Imoto et al., 2006). After 3 weeks of incubation with appropriate concentrations of G418 in six-well plates or 100-mm culture dishes, cells were fixed with 70% ethanol and stained with crystal violet.
Transfection with synthetic small interfering RNA
PRTFDC1-specific siRNA (PRTFDC1-siRNA) was purchased from Dharmacon (Lafayette, CO, USA). A control siRNA for the luciferase gene (IndexTermCGUACGCGGAAUACUUCGA, Luc-siRNA) was synthesized by Sigma. Each siRNA (50 nM) was transfected into OSCC cells (St. Louis, MO, USA) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The numbers of viable cells 24–96 h after transfection were assessed by a colorimetric water-soluble tetrazolium salt (WST) assay as described elsewhere (Saigusa et al., 2007). The cell cycle was analysed using FACS as described elsewhere (Saigusa et al., 2007).
Akanuma D, Uzawa N, Yoshida MA, Negishi A, Amagasa T, Ikeuchi T . (1999). Inactivation patterns of the p16 (INK4a) gene in oral squamous cell carcinoma cell lines. Oral Oncol 35: 476–483.
Baldwin C, Garnis C, Zhang L, Rosin MP, Lam WL . (2005). Multiple microalterations detected at high frequency in oral cancer. Cancer Res 65: 7561–7567.
Brinkman BM, Wong DT . (2006). Disease mechanism and biomarkers of oral squamous cell carcinoma. Curr Opin Oncol 18: 228–233.
Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM et al. (1986). A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (London) 323: 643–646.
Fujimoto R, Kamata N, Yokoyama K, Taki M, Tomonari M, Tsutsumi S et al. (2002). Establishment of immortalized human oral keratinocytes by gene transfer of a telomerase component. J Jpn Oral Muco Membr (Japanese) 8: 1–8.
Ha PK, Califano JA . (2006). Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7: 77–82.
Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E et al. (1996). DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Wash. DC) 271: 350–353.
Hermsen MA, Joenje H, Arwert F, Braakhuis BJ, Baak JP, Westerveld A et al. (1997). Assessment of chromosomal gains and losses in oral squamous cell carcinoma by comparative genomic hybridisation. Oral Oncol 33: 414–418.
Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F et al. (2006). Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res 66: 4617–4626.
Inazawa J, Inoue J, Imoto I . (2004). Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 95: 559–563.
Izumi H, Inoue J, Yokoi S, Hosoda H, Shibata T, Sunamori M et al. (2005). Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet 14: 997–1007.
Jin C, Jin Y, Wennerberg J, Annertz K, Enoksson J, Mertens F . (2006). Cytogenetic abnormalities in 106 oral squamous cell carcinomas. Cancer Genet Cytogenet 164: 44–53.
Jones PA, Baylin SB . (2002). The fundamental role of epigenetics events in cancer. Nat Rev Genet 3: 415–428.
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV et al. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science (Wash DC) 264: 436–440.
Kolb A . (2003). The first intron of the murine β-casein gene contains a functional promoter. Biochem Biophys Res Commun 306: 1099–1105.
Kusumoto Y, Hirano H, Saitoh K, Yamada S, Takedachi M, Nozaki T et al. (2004). Human gingival epithelial cells produce chemotactic factors Interleukin-8 and Monocyte Chemoattractant Protein-1 after stimulation with Porphyromonas gingivalis via Toll-Like Receptor 2. J Perioodontl 75: 370–378.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Wash. DC) 275: 1943–1947.
Misawa A, Inoue J, Sugino Y, Hosoi H, Sugimoto T, Hosoda F et al. (2005). Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplicon. Cancer Res 65: 10233–10242.
Nagpal JK, Das BR . (2003). Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. Oral Oncol 39: 213–221.
Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, Satoh Y et al. (2003). Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22: 8835–8844.
Nicklas JA . (2006). Pseudogenes of the human HPRT1 gene. Environ Mol Mutagen 47: 212–218.
Parkin DM, Bray F, Ferlay J, Pisani P . (2005). Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108.
Saigusa K, Imoto I, Tanikawa C, Aoyagi M, Ohno K, Nakamura Y et al. (2007). RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. Oncogene 26: 1110–1121.
Scully C, Field JK, Tanzawa H . (2000). Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN). I. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol 36: 256–263.
Shaw R . (2006). The epigenetics of oral cancer. Int J Oral Maxillofac Surg 35: 101–108.
Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J et al. (2001). Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 29: 263–264.
Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC et al. (2005). Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 24: 4232–4242.
Sonoda I, Imoto I, Inoue J, Shibata T, Shimada Y, Chin K et al. (2004). Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res 64: 3741–3747.
Takada H, Imoto I, Tsuda H, Nakanishi Y, Ichikura T, Mochizuki H et al. (2005b). ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene 24: 8051–8060.
Takada H, Imoto I, Tsuda H, Nakanishi Y, Sakakura C, Mitsufuji S et al. (2006). Genomic loss and epigenetic silencing of very-low-density lipoprotein receptor involved in gastric carcinogenesis. Oncogene 25: 6554–6562.
Takada H, Imoto I, Tsuda H, Sonoda I, Ichikura T, Mochizuki H et al. (2005a). Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci 96: 100–110.
Wolff E, Girod S, Liehr T, Vorderwulbecke U, Ries J, Steininger H et al. (1998). Oral squamous cell carcinomas are characterized by a rather uniform pattern of genomic imbalances detected by comparative genomic hybridisation. Oral Oncol 34: 186–190.
Xiong Z, Laird PW . (1997). COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532–2534.
We are grateful to Professor Yusuke Nakamura (Human Genome Center, The Institute of Medical Science, The University of Tokyo) for his continuous encouragement throughout this work. We thank Ai Watanabe, Ayako Takahashi and Rumi Mori for technical assistance. This work was supported by Grants-in-Aid for Scientific Research on Priority Areas (C) and 21st Century Center of Excellence Program for Molecular Destruction and Reconstitution of Tooth and Bone from the Ministry of Education, Culture, Sports, Science and Technology, Japan; and by a Grant-in-Aid from Core Research for Evolutional Science and Technology (CREST) of the Japan Science and Technology Corporation (JST).
About this article
Cite this article
Suzuki, E., Imoto, I., Pimkhaokham, A. et al. PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation. Oncogene 26, 7921–7932 (2007). https://doi.org/10.1038/sj.onc.1210589
- oral squamous-cell carcinoma
- homozygous deletion
Detection of dioxin-induced demethylation of mouse Cyp1a1 gene promoter by a new labeling method for short DNA fragments possessing 5'-methylcytosine at the end
Genes and Environment (2018)
BMC Cancer (2016)
Applied Biochemistry and Biotechnology (2015)
Stabilization of phenotypic plasticity through mesenchymal-specific DNA hypermethylation in cancer cells
Clinical Epigenetics (2011)